This paper introduces methods for use in vaccine clinical trials to help determine if the immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the HIV-specific immune response in placebo recipients would have been, had they been vaccinated, this immune response could be treated essentially like a baseline covariate and an interaction with treatment could be evaluated. Relatedly, the rate of infection by this baseline covariate could be compared between the two groups and a causative role of immune response would be supported if infection risk decreased with increasing HIV immune response only in the vaccine group. We introduce two methods for inferring this HIV-specific immune response. The first involves vaccinating everyone before baseline with an irrelevant vaccine, e.g. rabies. Randomization ensures that the relationship between the immune responses to the rabies and HIV vaccines observed in the vaccine group is the same as what would have been seen in the placebo group. We infer a placebo volunteer's response to the HIV vaccine using their rabies response and a prediction model from the vaccine group. The second method entails vaccinating all uninfected placebo patients at the closeout of the trial with the HIV vaccine and recording immune response. We pretend this immune response at closeout is what they would have had at baseline. We can then infer what the distribution of immune response among placebo infecteds would have been. Such designs may help elucidate the role of immune response in preventing infections. More pointedly, they could be helpful in the decision to improve or abandon an HIV vaccine with mediocre performance in a phase III trial.
Introduction
A vaccine contains innocuous material that provokes a response by the adaptive immune system. Following vaccination, the immune systems mounts a multi-faceted, and exquisitely specific counter-attack based on two types of white blood cells; B-lymphocytes and T-lymphocytes. These cells respond to specific proteins of the vaccine material, proliferate and wait to subsequently attack either floating microbes or infected cells that display such peptides. B-lymphocytes produce antibodies which recognize proteins in the outer surface of the virus and neutralize their ability to infect cells. T-lymphocytes produce cells which either kill or aid in killing infected cells. The magnitude of each component of the adaptive immune response to the vaccine can be measured. Vaccine development focuses on inducing a strong, measurable immune response while ensuring that the vaccine is safe (see e.g. Halloran 1998 , Nabel 2001 , or Chan, Wang, & Heyse 2003 .
Establishing the role of vaccine induced immune response on actual protection of infection and disease is an important open problem in vaccine studies (Halloran 1998) . A "correlate of protection" is the threshold for immune response, say x p , beyond which infections and disease do not occur (Lachenbruch et al 2000) . Methods for estimating such a threshold are discussed in Plikaytis & Carlone (2005) , Chan et al (2002) , and Carey, Barker & Platt (2001) . However, when immune response only occurs in the vaccinated group, validation of a correlate of protection, or more generally validation of of immune response as a true surrogate with a causative role, is problematic (Chan, Wang & Heyse 2003) . Strictly speaking, one cannot know whether the measured immune responses, or other unmeasured vaccine induced changes are actually responsible for an efficacious vaccine. For example, it could be that those individuals who achieve x p in response to a weak vaccine are more instrisincally fit than others so that even if a more powerful vaccine achieved x p in everyone, not all would be protected.
That this might be an actual problem was demonstrated in VAX004, the first phase trial III of an HIV vaccine (The rgp 120 HIV Vaccine Study Group 2005 , Gilbert et al 2005 .
Overall, the vaccine was not effective, with infection rates of .067 and .070, respectively, in the vaccine and placebo groups based on 5403 volunteers. However, the antibody response to the HIV vaccine was strongly associated with infection risk in the vaccine group. Table 1 provides the relative hazard of infection as a function of antibody response quartiles, first within the vaccine group and then when the placebo group is used as a control (see Gilbert et al 2005) . Because antibody response to the HIV vaccine is only measured in the vaccine group, the latter half of the table has question marks in the placebo cells.
Two hypotheses were postulated to explain these results (Gilbert et al 2005 , Graham & Mascola 2005 . The first was that antibody response is identifying volunteers with different constitutional ability to avoid infection but the vaccine induced immune response had no causative role. Call this the association hypothesis. The second was that the vaccine caused infections in those with the weakest immune response and prevented infections in those with the strongest immune response. Call this the causation hypothesis. As it stands, neither of these hypotheses can be evaluated on the basis of data.
In this paper we introduce two new designs to help understand the role of immune response in vaccines. These designs can discriminate between the two hypotheses outlined above. The first design is to inoculate everyone in both arms prior to randomization with an irrelevant vaccine, say rabies. Call this baseline irrelevant vaccination (BIV), and let W 0 be the immune response to the rabies vaccine at baseline. Also define X 0 as the immune response to the HIV-vaccine, which is measured just after randomization in the vaccine group.
Randomization ensures that the relationship between W 0 , X 0 observed in the vaccine group is the same in the placebo group. Based on this relationship, the observed W 0 of a placebo participant can be used to infer his X 0 . Figure 1 illustrates how W 0 can be used to impute X 0 in the placebo group when they are very highly correlated (ρ = .98). It is important to note that a rabies vaccine is not required-any baseline measurement that correlated well with X 0 would work, but an irrelevant vaccinization is a good choice. This type of thinking to predict a post-randomization characteristic only observed in the treatment group has been used before in heart disease (see e.g. Hallstrom et al 2001 , or Follmann 2000 .
The second way to get at X 0 in the placebo group would be to vaccinate all the uninfected placebo recipients at the closeout of the trial with the HIV vaccine and then measure their immune response, say X C . If we make the assumption that X C is the same as X 0 , we effectively obtain X 0 in many. Call this closeout placebo vaccination (CPV). Table 2 provides hypothetical data illustrating how CPV can be used to suggest that X 0 is associated with constitutional ability to remain uninfected, but has no causative role. Figure 1 and Table 2 are meant to informally illustrate how to infer X 0 in the placebo group. In the sequel, we develop formal methods that rely on the thinking of counterfactuals and causal inference. We also describe some simple methods, investigate performance of different methods by simulation, and discuss some more elaborates approaches.
Model Based Approach
Suppose that n patients per group are randomized to placebo or vaccine. Prior to randomization, all patients receive a rabies vaccine and the immune response to rabies vaccine, (W 0 ), is measured before randomization. Patients are then randomized to either a placebo or HIV vaccine injection and shortly thereafter, immune response to the HIV vaccine (X 0 ) is measured in the vaccine group. At the closeout or end of the trial, all uninfected placebo recipients receive the HIV vaccine and shortly thereafter, immune response to this vaccine is measured (X C ). Let Y be the infection indicator and Z be the vaccine indicator. A schematic representation of a vaccine trial augmented with BIV and CPV is given in Figure   2 .
Our approach to using these data is perhaps best described using counterfactual reasoning (Neyman 1923 , Rubin 1974 , 1977 , 1978 , and Halloran & Struchiner 1995 . First, let W 0i be the baseline rabies-specific adaptive immune response for patient i. This is seen in everyone. The response to HIV vaccination is different. One can write X 0i (z) as the (post) baseline HIV-specific immune response to HIV vaccination. We call X 0i (0), X 0i (1) potential covariates; X 0i (1) is measured in vaccine recipients while X 0i (0) is not measured nor meaningful. We say that X 0i (1) is realized in the vaccine group and unrealized in the placebo group. We next define Y i (z) as the outcome for person i following treatment z. We call the pair Y i (0), Y i (1) potential outcomes. We also define X Ci (z, y) as the closeout HIV-specific adaptive immune response for person i when given treatment z and following outcome y.
Only X Ci (0, 0) is measured and meaningful.
We make the following simplifying assumptions.
• All patients receive the assigned injections so there is no noncompliance.
• There is no missing data; W 0 , Y 0 are measured on everyone, X 0 is measured on all vaccinees and X C is measured on all placebo uninfecteds.
• No infections occur between the time of randomization and when X 0 is measured, say
The first two are for simplicity and can be relaxed. For example, if there is some noncompliance but it is governed an independent random mechanism, our methods could be applied to just the compliers. With data missing completely at random the methods can be applied directly to the observed data. If the data are missing at random, methods that incorporate covariates associated with missingness can be used. The last assumption is more likely to be met if m is small. If a few infections occur in [0, m] an analysis that throws them may be acceptable. We discuss how to modify our approach to incorporate infections during [0, m] in section 6.
We next specify probit models for the effect of the "baseline covariate" X 0 (1) on the probability of infection in both groups: (2004) we define vaccine efficacy as
With our probit model, a natural estimand is
Note that when β 3 = 0, ∆ P (x) is free of x, this is not true for V E(x).
If X 0i (1) were observed in everyone, estimation would be straightforward. Since X 0i (1) is not observed in the placebo group, we require at least one of the following two assumptions to proceed:
• X 0i (1) can be viewed as a baseline covariate or
• For placebo uninfecteds, X 0i (1) = x i + U 1 and X Ci (0, 0) = x i + U 2 where U 1 and U 2 are iid mean 0. Call this time constancy of immune response.
The first assumption is true by design in randomized trials and allows us to impute X 0i (1) based on W 0i in the placebo group. While technically measured post-randomization this "post-baseline" covariate can be used as a baseline covariate. The second assumption allows us to replace X 0i (1) with X Ci (0, 0) as a covariate in the probit model for placebo uninfecteds. Under the model X = x + U , one can think of x as the true time constant immune response which is observed subject to measurement error and our interest focuses on the regression of Y on X. This assumption cannot be accepted uncritically as immune response can diminish with age, such as for herpes zoster, if the trial is long enough. Additionally volunteers might get subinfectious exposures to a virus that modifies immune response. This is thought possible for HIV where commercial sex workers showed immune responses to HIV but remained uninfected. However even here, the assumption might hold if the immune response is effectively primed by subinfectious exposure pre-baseline and this response is maintained during the course of the trial. Additionally, this assumption can be examined, as we will discuss in section 6.
Our final assumption allows us to easily integrate over the distribution of
This assumption can also be relaxed but the integration would be more complicated.
To estimate β = (β 0 , β 1 , β 2 , β 3 ), we use maximum likelihood. We begin by constructing a likelihood incorporating both BIV and CPV. The likelihood contribution for vaccinees is simple,
where V is the set of vaccinees. For uninfected placebo volunteers we use X Ci in lieu of X 0i
and their contribution is
where P(U) is the set of uninfected placebo recipients. In the placebo infecteds, X 0 (1) is missing and we need to integrate p 0 (X 0 (1)) over the distribution of X 0 (1)|W 0 , to obtain their likelihood contribution. Under our last assumption, it follows that X 0 (1)|W 0 = w is normal
probability of infection for a person with W 0 = w 0 is thus
The RHS obtains by the result that
The overall likelihood is thus
Note that p * 0 (w 0i ) depends on the moments of X 0 (1), W 0 which are unknown. We advocate estimating these moments using vaccine group data and regard them as fixed in L BC . Because of this, the standard error estimates obtained by the Fisher information matrix are incorrect and we suggest using the nonparametric bootstrap method to obtain standard errors.
We can also construct likelihoods based on augmenting the usual design with BIV alone or CPV alone. These are, respectively,
where P is the set of placebo recipients, and
, where #P(I) is the number of placebo infecteds. The last Φ() in L C (β) is just the probability a generic placebo patient is infected and equals
. Based on the estimated βs it is a simple matter to plug them into a causal estimand.
Standard errors and confidence intervals for causal estimands can be computed from the bootstrap.
Closeout Placebo Vaccination Alone
The previous section outlined how BIV and CPV can be used to estimate the effect of immune response using a model and likelihood. In this section, we show how closeout placebo vaccination by itself can be used without a model to assess immune response. The approach is inspired by Table 1 and Gilbert, Bosch, & Hudgens (2003) .
Denote by f 0 (x) and f 1 (x) the densities of X 0 (1) for the placebo and vaccine groups, respectively. In each group we can decompose the distribution of immune response into a mixture of those who would/did become infected and those who wouldn't/didn't. Thus we can write the immune response densities in mixture form:
where θ is the true proportion of infected volunteers in group . In the vaccine group the mixed density and the two constituent densities are directly estimable as is θ 1 . In the placebo group θ 0 and f 0 (x|Y = 0) are directly estimable, provided (X 0 (1)|Y = 0)
we replace f 0 (x) with f 1 (x) and solve by subtraction.
With these arguments and Bayes Theorem, one can deduce that
The terms on the RHS can be estimated nonparametrically and thus so can the LHS.
Interestingly, the different conditional distributions of X 0 (1) can be compared to test the role of X 0 (1). To motivate these tests, consider Table 1 . Suppose the counts in the Placebo Uninfected row were very similar over the 4 quartiles. This would suggest that unrealized potential immune response was unassociated with infection risk. Using the fact that f 1 (x) = f 0 (x), the continuous analogue to seeing if the counts in the Placebo Uninfected row are similar can be written as
Note that if the probit model (1) corresponds to the causation hypothesis that was suggested to explain Table 1 .
At the other extreme, suppose that the counts in the Vaccine Uninfected row were quite similar to the counts in the Placebo Uninfected row. This would suggest immune response has no causative effect on infection. The continuous analogue is 
Simulation
To assess these designs, we conducted a simulation under the model assumptions given in the previous section. We generated data where P (Y (z) = 1|Z = z, X 0 (1) = x) is given by (1), and W 0 , X 0 (1) are bivariate Gaussian with correlation ρ. We set E[p 0 (X 0 (1))] = θ 0 = .10 and θ 1 = .08. We selected β 2 , β 3 in terms of relative risk,
where Q(7/8), Q(1/8) are the 7th and 1st octiles of the distribution of X 0 (1). Three scenarios were considered, chosen with the hazards of Table 1 in mind.
• Assocation: Here R 1 = R 0 = .2 ,β 3 = 0 and ∆ P (x) is free of x.
• Causation: Here R 0 = 1, R 1 = .2, β 2 = 0 and ∆ P (x) depends on x.
• Both:
For each simulated data set maximum likelihood using L BC , L B , and L C was used to estimate β. We also constructed a probit likelihood based on observing X 0 (1) exactly in everyone. Estimates based on this likelihood correspond to an unattainable benchmark.
The first set of simulations used 10,000 replications and varied .25, .5, .75, 1. We do not evaluate ρ = 0 as the model using BIV alone is unidentifiable. Replications were not tallied when convergence was not attained which was very rare except for BIV alone with ρ = .25, when the estimates did not converge 2-3% of the time. and CPV+BIV, have similar variance ratios. We see that for large ρ CPV is unnecessary and for small ρ BIV performs poorly. For ρ = .25 both CPV and BIV are helpful.
Our second set of simulations evaluate power and are given in Table 3 with n = 1000 or 2500, ρ = .25 or .50, and for the three scenarios: Association, Causation and Both. For the Wald tests, a nonparametric bootstrap standard error was calculated using the sample variance of 100 bootstrap resamples for each simulated trial. Resamples where convergence was not attained were thrown out which was rare except for BIV alone with ρ = .25. As before, BIV alone with ρ = .25 had problems with convergence and these were exacerbated in the bootstrap resamples.
We begin by evaluating the Wald test. First, the benchmark has extremely high power, except for β 3 under scenario B with n = 1000. For CPV+BIV, power is generally good to excellent for all scenarios with n=2500. For n=1000, power is degraded, especially with ρ = .25. For BIV alone, power is similar to CPV+BIV for ρ = .50 and much worse for ρ = .25. Generally, power for CPV alone is much worse than for BIV alone with ρ = .50 and moderately better with ρ = .25. The power of the t-tests is usually similar to CPV alone and close to at least .50 for scenarios A and C with n = 2500.
We also did a few limited simulations to address specific issues. In practice, one might want to perform CPV on a fraction of the placebo uninfecteds. For scenario A, we compared the estimates using CPV alone where X C was obtained on everyone to where it was obtained on 1/2, 1/4, or 1/10 of the placebo uninfecteds. The sampling variance for eitherβ 2 orβ 3 was about 60%, 300% and 1000% larger than when X C was obtained in everyone, respectively.
Second, we evaluated the procedures when the moments were set to their true values and not estimated. The sampling variance for CPV alone and for BIV alone was nearly halved when true values were used instead of estimated. For CPV+BIV, the sampling variability was only modestly reduced. For larger trials e.g. n = 8000 with low event rates, the performance of CPV and BIV relative to BIV+CPV might be better than shown in Figure 3 and Table   3 as the estimated moments of X 0 (1), W 0 would be more reliable. It also suggests that one might want to consider use of a full likelihood. For example, for CPV alone use
where φ(x; µ, σ 2 ) is the normal density and f 0 (x iC |Y i = 0; µ x , σ 2 x ) is the density for uninfecteds, derived under (1) and a Gaussian model for X 0 (1).
In summary, the new designs can be efficient and powerful even with n = 1000 if ρ > .5.
If ρ is modest, a larger sample size is required to achieve strong power as CPV is necessary.
If ρ is large enough, CPV may be unnecessary, while if ρ is too small, BIV alone may be useless. With n = 2500 we have excellent power for scenarios A and C with ρ = .5 using BIV alone and good to excellent power with the BIV+CPV combination with ρ = .25. Even with CPV alone, power is greater than 50% for these two scenarios. This configuration is not unlike VAX004 suggesting augmented designs could have helped inform the debate about these two hypotheses. It is clear that the performance of the designs depends dramatically on specific scenarios. In practice, careful analysis of performance would be required to settle on a specific augmented design.
We note that a correlation of close to .5 may be a realistic aspiration. In the VAX004 trial, the vaccine consisted of two strains of viral gp-120 which is a sequence of 120 amino acids that comprise the outer envelope of the virus. The two strains were denoted MN, and GNE8. 
Elaborations
The 
then
is consistent with time constancy of immune response. Note that H
T W 0 can be tested using data readily available from a CPV trial and does not require a partial closeout, halfway through the trial.
Model (1) assumes that there is no effect of W 0 on infection risk once X 0 (1) is in the model. One can specify generalizations to (1) that include W 0 as an additional main effect, or even allow for interaction with treatment,
and likelihood construction for this model would parallel construction based on (1). It is perhaps surprising that even for our setting where X 0 (1) is missing in the placebo group, this model with two interactions can be estimated provided CPV is performed. If CPV is not done, (8) is identifiable provided, e.g. β 5 = 0. With CPV one could test whether β 5
and/or β 3 were 0. However, such tests would likely have poor power, as trials are powered for a treatment main effect and estimating two interactions may be difficult.
In principle, W 0 could be any baseline variable correlated with X 0 (1) and a baseline irrelevant vaccination need not be performed. Presumably, however, W 0 based on BIV should have a much stronger relationship with X 0 (1) than a variable such as race, gender, or
age. An additional issue with non-immunologically based W 0 is the perhaps greater concern that β 3 and or β 5 in (8) might not be zero. It is important to realize that if (8) holds with (β 3 , β 5 ) = (0, 0) then inference derived from fitting (the incorrect) model (1) would be misleading.
We made a simplifying assumption that there were no infections in either group until after X 0 (1) was measured. If infections do occur over the interval [0, m] we can still obtain consistent estimates of the parameters provided we derive a likelihood under more assumptions. We illustrate one way. Consider a BIV design. Since the likelihoods in section 2 
where φ is the bivariate normal density function.
Final Comments
While this paper has focused on immune response to an HIV vaccine, it is clear that the methods would apply to any vaccine trial. Chan, Wang, & Heyse (2003) CPV offers protection against this possibility. Finally, a simple t-test based on CPV data alone is appealing for its simplicity and transparency. Of course, CPV requires the strong assumption of time constancy of immune response.
In practice, several vaccinations over several months may be necessary during which time infections might accrue and the immune responses might wax and wane in conjunction with the vaccinations so thought is required to pick a precise time to measure X 0 (1). Another approach would be do develop methods that explicitly model the time-varying nature of X 0 (1) and use time to infection as the outcome rather than a binary indicator of infection.
Implementation of these designs could be done in an incremental fashion. Initially, small studies could be conducted to establish the extent of correlation between W 0 and X 0 (1), which irrelevant vaccine was most useful, and whether time constancy of immune response were plausible. If promising, an adaptive augmented phase III design could then be initiated.
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